Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022

Bibliographic Data

ID11036077
AuthorsFan Xiong (0009-0003-1375-4004, Fan Xiong and Jillian Jetson are with the Washington State Department of Health, Tumwater, Washington. Cheolwoo Park is with the Department of Mathematical Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of South Korea. Chris Delcher is with the Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.), Jillian Jetson (Fan Xiong and Jillian Jetson are with the Washington State Department of Health, Tumwater, Washington. Cheolwoo Park is with the Department of Mathematical Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of South Korea. Chris Delcher is with the Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.), Cheolwoo Park (0000-0001-8337-9180, Fan Xiong and Jillian Jetson are with the Washington State Department of Health, Tumwater, Washington. Cheolwoo Park is with the Department of Mathematical Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of South Korea. Chris Delcher is with the Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.), Chris Delcher (0000-0001-7214-0326, Fan Xiong and Jillian Jetson are with the Washington State Department of Health, Tumwater, Washington. Cheolwoo Park is with the Department of Mathematical Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic of South Korea. Chris Delcher is with the Institute for Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Kentucky, Lexington.)
Year2024
Volume114
Issue7
Pages696-704
Publication date2024-07-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueAmerican Journal of Public Health (JOURNAL)
Journal identifiersISSN: 0090-0036 • E-ISSN: 1541-0048
PublisherAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2024.307649
PMID38696736
OpenAlexW4396599490
LanguageEN
Citations received1
References cited30

Objectives. To evaluate changes in monthly buprenorphine dispensation associated with federal prescribing policies in Washington State from 2012 to 2022. Methods. We conducted an interrupted time series analysis comparing monthly buprenorphine prescriptions dispensed per 1000 population after the Comprehensive Addiction and Recovery Act (CARA), Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT), and new prescribing rules during the COVID-19 pandemic. Buprenorphine formulated for opioid use disorder was included from the Washington State Prescription Monitoring Program. A log-linear autoregressive model measured linear trend changes. Results. Physician prescribing increased by 1.63% (95% confidence interval [CI] = 1.41%, 1.85%) per month after CARA with sustained declines after SUPPORT. Nurse practitioner (NP) prescribing increased by 19.48% (95% CI = 18.8%, 20.16%) per month after CARA with physician assistants (PAs) showing similar trends. Following the implementation of SUPPORT, NP and PA trends continued to increase at a reduced growth rate of 3.96% (95% CI = 2.01%, 5.94%) and 1.87% (95% CI = 0.56%, 3.19%), respectively. No prescribers experienced increases during the COVID-19 pandemic. Conclusions. CARA nearly tripled the buprenorphine prescribing rate. The SUPPORT Act initiated sustained declines for physician prescribing, and the COVID-19 period reversed gains for PAs and NPs. The current opioid crisis requires expanded efforts in Washington State. ( Am J Public Health. 2024;114(7):696–704. https://doi.org/10.2105/AJPH.2024.307649 )

Buprenorphine · Environmental health · Opioid · Antibiotic Use and Resistance · Internal Medicine · Medicine · Opioid Use Disorder Treatment · Poisoning and overdose treatments

Tools

Open DOIOpen Access